Email this article 
Post a Comment 
Hide
Show all
A importância da idade na síndrome metabólica em pacientes portadoras de ovários policísticos
Abstract
(MBS) in sergipanas women with polycystic ovary syndrome (PCOS) using age as an association
variable. It is a cross-sectional study involving 50 women aged 25-50 years old with PCOS in accord
with Rotterdam criteria (2003). For the diagnosis of metabolic syndrome, the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III) was considered. The prevalence of the
MBS was 56%. As for the individual components of MS, was evident: abdominal circumference > 88
cm in 72%, triglycerides ≥ 150 mg/dL in 32%, HDL-cholesterol <50 mg/dl in 54%, fasting glucose ≥ 110
mg/dl in 26%, systolic blood pressure ≥ 130 mmHg in 52% and diastolic blood pressure ≥ 85 mmHg in
40%. Patients aged equal or over 35 years had a higher percentage of Abdominal Circumference (AC)
> 88 cm (40%), modified triglyceride levels (20%), HDL-cholesterol to levels below 50 mg/dl (34%),
altered levels of fasting glucose (22%), systolic blood pressure (SBP) equal to or above 130 mmHg
(36%) and diastolic blood pressure (DBP) equal to or above 85 mmHg (26%). There was a statistically
significant association (p <0.05) between age and the following variables: AC, triglycerides, fasting
glucose and DBP. There was a significant prevalence of MS in more than half the women studied,
indicating increased chances for developing cardiovascular disease (CVD) and pointing out the need for
tracking cardiovascular risk among women with clinical manifestations of PCOS.
Keywords
Full Text:
PDFReferences
Gadelha RGN, Soares EMM, Silva TMA, Maranhão TMO,
Azevedo GD. Síndrome dos ovários policísticos e síndrome:
uma associação significativa com implicações clínicas.
PublICa. 2005;1(2):68-77.
Fernandes LG. Síndrome dos ovários policísticos: uma
abordagem epidemiológica [tese]. Salvador (BA): Universidade
Federal da Bahia, Instituto de Saúde Coletiva,
Programa de Pós-Graduação em Saúde Coletiva; 2013.
Legro RS. Diagnostic criteria in polycystic ovary syndrome.
Seminars in reproductive medicine. 2003;21(3):267-75.
Speroff LGR, Kase NG. Anovulation and the Polycystic
Ovary. In: Weinberg R, editor. Clinical Gynecologic Endocrinology
and Infertility. Philadelphia: Lippincott Williams
and Wilkins; 2005. p.465-98.
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med.
;352(12):1223-36.
Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease
in the polycystic ovary syndrome: new insights and
perspectives. Atherosclerosis. 2006;185(2):227-39.
Fernández-Morales D. Manifestaciones clínicas del síndrome
del ovario poliquístico. Acta Médica Costarricense.
;47(4):180-5.
Bhatia V. Insulin resistance in polycystic ovary disease.
South Med J. 2005;98(9):903-10.
Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka
G, Hill M, et al. Insulin Sensitivity in women with
polycystic ovary syndrome. J Clin Endocrinol Metab.
;89(6):2942-5.
Trolle B, Lauszus FF. Risk factors for glucose intolerance
in Danish women with polycystic ovary syndrome. Acta
Obstet Gynecol Scand. 2005;84(12):1192-6.
Wild S, Pierpoint T, McKeighe P, Jacobs H. Cardiovascular
disease in women with polycystic ovary syndrome
at long-term follow-up: a retrospective cohort study. Clin
Endocrinol (Oxf). 2000;52(5):595-600.
Legro RS. Polycystic ovary syndrome and cardiovascular
disease: a premature association? Endocr Rev.
;24(3):302-12.
Meyer C, McGrath BP, Teede HJ. Overweight women
with polycystic ovary syndrome have evidence of subclinical
cardiovascular disease. J Clin Endocrinol Metab.
;90(10): 5711-6.
Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão
TM. Prevalence of the metabolic syndrome and
its components in Brazilian women with polycystic ovary
syndrome. Fertil Steril. 2008;89(3):649-55.
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS,
Ghazzi MN, et al. Prevalence and predictors of the metabolic
syndrome in women with polycystic ovary syndrome.
J Clin Endocrinol Metab. 2006;91(1):48-53.
Meirelles RMR. Menopausa e síndrome metabólica. Arq
Bras Endocrinol Metab. 2014;58(2):91-6.
Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-
-specific prevalence of the metabolic syndrome defined
by the International Diabetes Federation and the National
Cholesterol Education Program: the Norwegian HUNT 2
study. BMC Pub. Health. 2007;7(220):1-9.
Szostak-Wegierek D, Waskiewicz A. Metabolic disorders
in women at procreative age living in Warsaw. Rocz
Panstw Zakl Hig. 2015;66(3):245-251.
Soares EMM, Azevedo GD, Maranhão TMO. Síndrome
Metabólica em Mulheres Com Síndrome dos Ovários Policísticos:
Prevalência em Cidade da Região Nordeste do
Brasil. Arq Bras Endocrinol Metab. 2007;51(6):1027:1028.
Gogia A, Agarwal PK. Metabolic syndrome. Indian J Med
Sci. 2006;60(2):72-81.
Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation
of metabolic syndrome frequency and premature
carotid atherosclerosis in young women with polycystic
ovary syndrome. Hum Reprod. 2005;20(9):2409-13.
Tehrani FR, Montazeri1 SA, Hosseinpanah F, Cheraghi L,
Erfani1 H, Tohidi M, et al. Trend of Cardio-Metabolic Risk
Factors in Polycystic Ovary Syndrome: A Population-Based
Prospective Cohort Study. PLoS ONE. 2015;10(9):1-
Costa LOBF, Viana AOR, Oliveira M. Prevalência da síndrome
metabólica em portadoras da síndrome dos ovários
policísticos. Rev Bras Ginecol Obstet. 2007;29(1):10–17.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group. Revised 2003 consensus on diagnostic
criteria and longterm health risks related to polycystic
ovary syndrome. Fertil Steril. 2004;81(1):19-25.
National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel
III). Third Report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) final report. Circulation.
;106(25):3143-421.
Puder JJ, Varga S, Kraenzlin M, de Geyter C, Keller U,
Müller B. Central fat excess in polycystic ovary syndrome:
relation to low-grade inflammation and insulin resistance.
J Clin Endocrinol Metab. 2005;90(4):6014-21.
Centers for Disease Control and Prevention. The Third
National Health and Nutrition Examination Survey (NHANES
III 1988-94) Reference Manuals and Reports. Bethesda,
Md: National Center for Health Statistics; 1996.
Ilanne-Parrika P, Eriksson JG, Lindstrom J, Hamalainen
H, Keinanen-Kiukaanniemi S, Laakso M, et al. Prevalence
of the Metabolic Syndrome and its Components. Diabetes
Care. 2004;27(9):2135-40.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic
syndrome among US adults: findings from the Third
National Health and Nutrition Examination Survey. JAMA.
;287(3):356-9.
Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence
and characteristics of the Metabolic Syndrome in
women with polycystic ovary syndrome. J Clin Endocrinol
Metab. 2005;90(4):1929-35.
Ávila MAP, Bruno RV, Barbosa FC, Andrade FC, Silva
ACO, Nardi AE. Síndrome dos ovários policísticos: implicações
da disfunção metabólica. Rev Col Bras Cir.
;41(2):106-11.
Premoli ACG, Moura MD, Ferriani RA, Sá MFS, Reis
RM. Perfil lipídico em pacientes portadoras da síndrome
dos ovários policísticos. Rev Bras Ginecol Obstetr.
;22(2):89-94.
Sathyapalan T, Atkin SL. Mediators of inflammation in
polycystic ovary syndrome in relation to adiposity. Mediators
inflammation. 2010;2010:1-5.
Costa EC, Soares EMM, Lemos TMAM, Maranhão TMO,
Azevedo GD. Índices de obesidad central y factores de
riesgo cardiovascular em el síndrome de ovarios poliquísticos.
Arq Bras Cardiol. 2010;94(5):615–20.
Kandaraki E, Christakou C, Diamanti-Kandarakis E. Metabolic
syndrome and polycystic ovary syndrome… and
vice versa. Arq Bras Endocrinol Metab. 2009;53(2):227-
Kuba VM, Cavaliere PM, Christóforo AC, Faria Júnior R,
Caetano R, Coeli CM, et al. Resistência insulínica e perfil
metabólico em pacientes com síndrome dos ovários
policísticos de peso normal e sobrepeso/obesidade. Arq
Bras Endocrinol Metab. 2006;50(6):1026–33.
Baldani DP, Skrgatic L, Ougouag Roya. Polycystic ovary
syndrome: important underrecognised cardiometabolic
risk factor in reproductive-age women. Inter J Endocrinol.
;2015:1-17.
Martins WP, Soares GM, Vieira CS, Reis RM, Sá
MFS, Ferriani RA. Resistência à insulina em mulheres
com síndrome dos ovários policísticos modifica fatores
de risco cardiovascular. Rev Bras Ginecol Obstet.
;31(3):111–6.
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors
of dyslipidemia in women with polycystic ovary
syndrome. Am J Med. 2001;111(8):607-13.
Hudecova M, Holte J, Olovsson M, Larsson A, Berne C,
Sundstrom-Paromaa I. Prevalence of the metabolic syndrome
in women with a previous diagnosis of polycystic
ovary syndrome: long-term follow-up. Fertility and Sterility.
;96(5):1271-4.
Gobato AO, Vasques ACJ, Zambon MP, Barros Filho
AA, Hessel G. Síndrome metabólica e resistência à
insulina em adolescentes obesos. Rev Paul Pediatr.
;32(1):55-62.
Passos VMA, Assis TD, Barreto SM. Hipertensão arterial
no Brasil: estimativa de prevalência a partir de estudos
de base populacional. Epidemiol Serv Saúde.
;15(1):35-45.
Dias-da-Costa JS, Olinto MTA, Patrussi AT. Prevalência
de hipertensão arterial sistêmica e fatores associados:
um estudo de base populacional em mulheres no Sul do
Brasil. Cad Saúde Púb. 2007;23(8):1857-66.
Faramawi MF, Delongchamp R, Said Q, Jadhav S, Abouelenien
S. Metabolic syndrome is associated with visit-to-
-visit systolic blood pressure variability in the US adults.
Hypertens Res. 2014;37(9):875-9.
DOI: http://dx.doi.org/10.22565/ijn.v9i2.241
Refbacks
- There are currently no refbacks.
